2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide
C21H20FN7OS — CID 147776440
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide
2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide (PubChem CID 147776440) has the molecular formula C21H20FN7OS and a molecular weight of 437.50 g/mol. Its IUPAC name is 2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide.
Molecular Properties
| Compound Name | 2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide |
|---|---|
| PubChem CID | 147776440 |
| Molecular Formula | C21H20FN7OS |
| Molecular Weight | 437.50 g/mol |
| Exact Mass | 437.14 |
| IUPAC Name | 2-fluoro-4-methyl-5-(2-methyl-1,3-thiazol-5-yl)-N-[6-(1-propan-2-yltetrazol-5-yl)-2-pyridinyl]benzamide |
| SMILES | Cc1ncc(-c2cc(C(=O)Nc3cccc(-c4nnnn4C(C)C)n3)c(F)cc2C)s1 |
| InChI | InChI=1S/C21H20FN7OS/c1-11(2)29-20(26-27-28-29)17-6-5-7-19(24-17)25-21(30)15-9-14(12(3)8-16(15)22)18-10-23-13(4)31-18/h5-11H,1-4H3,(H,24,25,30) |
| InChIKey | HGXWVGGKZKZCLY-UHFFFAOYSA-N |
| XLogP | 4.45 |
| TPSA | 98.48 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 8 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 437.50 |
| LogP ≤ 5 | 4.45 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 8 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 147776440 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.